
Veracyte Investor Relations Material
Latest events

Q1 2025
Veracyte
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Veracyte Inc
Access all reports
Veracyte, Inc. develops and commercializes blood tests for the early detection of lung cancer and emphysema. The company offers Veracyte Drug Screening Assay and Veracyte Acute Exacerbation Panel (V-AEP) for the detection of Lung Cancer and Chronic Obstructive Pulmonary Disease (COPD). Its drug screening assays are based on a proprietary approach of analyzing patient genomic data to predict which patients are most likely to have cancer after receiving a lung CT scan. The company markets its products through direct sales force, as well as through clinical laboratory partners, medical practitioners, and directly to patients.
Key slides for Veracyte Inc


Q2 2024
Veracyte Inc


Q1 2025
Veracyte Inc
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
VCYT
Country
🇺🇸 United States